Thiruvalla's Pigmentation Correction Experts

Melasma Treatment in Thiruvalla
Expert Pigmentation & Dark Spot Removal

High year-round UV exposure drives stubborn melasma. DermaVue treats the root cause with Q-switched laser, combination peels, and protocols tailored for South Indian skin.

3,221 Reviews Google 4.8★ MD DVL Specialists Board-Certified US-FDA Approved Equipment IADVL Registered Dermatologists Hospital-Standard Sterile OT
⭐ 4.8★ Google Rating ✅ 3,221+ Patient Reviews 🏥 7 Clinics Across South India 👨‍⚕️ MD DVL Board-Certified 🔬 US-FDA Approved Equipment 📍 Opposite Indian Overseas Bank, Thukalassery
Melasma pigmentation treatment in Thiruvalla — Q-switched laser dark spot removal DermaVue dermatologist Kerala

Understanding Melasma: Pathophysiology, Classification & Kerala Climate

Quick Answer

Melasma treatment in Thiruvalla/Tiruvalla follows the Pigmentary Disorders Academy protocol: Wood lamp classification (epidermal, dermal, mixed), modified Kligman trio (hydroquinone 4% + tretinoin 0.025% + hydrocortisone) as first-line, oral tranexamic acid 250 mg twice daily for resistant cases (with contraindication screening), low-fluence Q-switched Nd:YAG 1064 nm toning over 6–10 sessions, and daily iron-oxide tinted sunscreen SPF 50+ PA++++ to block visible light. Treatment is long-term; sun protection is non-negotiable.

DermaVue Clinical Summary — Melasma

Melasma is an acquired chronic symmetrical hypermelanosis of sun-exposed skin, characterised histologically by increased melanogenesis in the epidermis and, in dermal variants, by melanin-laden macrophages within the papillary dermis. The condition disproportionately affects Fitzpatrick skin types III–V — the predominant phototype across South India — with a strong female predominance and associations with pregnancy, combined oral contraceptives, thyroid dysfunction, and cumulative ultraviolet and visible-light exposure (Passeron & Picardo, Pigment Cell & Melanoma Research 2018). Kerala's near-equatorial latitude, year-round high UV index, and increasing visible-light exposure from digital devices together make melasma one of the most common pigmentary presentations at DermaVue Thiruvalla.

Clinical evaluation begins with Wood's lamp examination to classify melasma as epidermal (enhanced contrast under Wood's light — best prognosis), dermal (no contrast enhancement — poorest prognosis), or mixed. Severity is documented using the Melasma Area and Severity Index (MASI) and modified MASI (mMASI) for reproducible response tracking. Treatment follows the IADVL Pigmentary Disorders consensus (IJDVL 2017): topical modified Kligman trio (hydroquinone 4% + tretinoin 0.025% + hydrocortisone 1%) as standard first-line, azelaic acid 20%, cysteamine 5% cream, topical tranexamic acid 5%, and kojic acid-arbutin combinations as adjuncts.

For refractory or dermal melasma, DermaVue prescribes oral tranexamic acid 250 mg twice daily for 8–12 weeks (Bala et al., JAAD 2018; Del Rosario et al., JAAD 2018) after screening for contraindications including personal or family history of deep vein thrombosis, pulmonary embolism, stroke, active malignancy, pregnancy, or concurrent combined oral contraceptive use. Procedural adjuncts include low-fluence Q-switched Nd:YAG 1064 nm laser toning (6–10 sessions, 2–4 weeks apart), modified Jessner peels, mandelic acid 20–40% peels, and TCA 15–20% spot peels — each selected by depth and Fitzpatrick type. Critically, daily broad-spectrum iron-oxide tinted sunscreen SPF 50+ PA++++ is prescribed to block both UVA/UVB and high-energy visible (HEV) light — the single most outcome-defining step in every protocol (Dumbuya et al., JDD 2020). Sources: IADVL (iadvl.org), IJDVL, AAD, PubMed, NIH.

Melasma — brown or grey-brown symmetrical facial patches — is among the most common pigmentary presentations at DermaVue Thiruvalla. High year-round UV and visible-light exposure, hormonal influences (pregnancy, combined oral contraceptives, thyroid dysfunction), and the Fitzpatrick III–V phototype predominant in Pathanamthitta district all contribute to both incidence and chronicity. Our protocols address melasma at epidermal, dermal and mixed depths for durable, individualised results.

  • Epidermal melasma — enhanced border contrast under Wood's lamp; best prognosis; responds to topical and superficial procedural therapy
  • Dermal melasma — no contrast under Wood's lamp; dermal melanophages; most resistant; requires combination systemic-procedural approach
  • Mixed melasma — features of both; commonest presentation in Kerala women
  • Centrofacial pattern — forehead, nose, upper lip, chin; most common distribution
  • Malar pattern — cheeks and nose
  • Mandibular pattern — along the ramus of the mandible; associated with photoageing
  • Post-inflammatory hyperpigmentation — following acne, eczema, or procedural injury
  • Solar lentigines, ephelides and drug-induced pigmentation — differentiated clinically and by dermoscopy

Understanding Melasma & Pigmentation Causes

DermaVue Thiruvalla Combination Melasma Protocol

Melasma is chronic and relapse-prone; monotherapy rarely produces durable results. DermaVue follows a structured stepwise combination approach guided by Wood's lamp depth classification, Fitzpatrick type, pregnancy status, and prior therapy history. Treatment response is documented with serial mMASI scoring and standardised photography every 4 weeks.

  • Modified Kligman trio (hydroquinone 4% + tretinoin 0.025% + hydrocortisone 1%) — first-line, 8–12 weeks, then pulsed maintenance
  • Oral tranexamic acid 250 mg BD × 8–12 weeks — after contraindication screening (DVT/PE/stroke/malignancy/pregnancy/COC)
  • Topical adjuncts: azelaic acid 20%, cysteamine 5%, topical tranexamic acid 5%, kojic acid-arbutin combinations, thiamidol
  • Low-fluence Q-switched Nd:YAG 1064 nm laser toning — 6–10 sessions, 2–4 weeks apart; dermal and mixed melasma
  • Superficial chemical peels: modified Jessner, mandelic acid 20–40%, TCA 15% spot peels — Fitzpatrick-adjusted
  • Iron-oxide tinted mineral sunscreen SPF 50+ PA++++ — blocks UVA/UVB and visible light; reapplied every 2–3 hours; non-negotiable
  • Hormonal review: thyroid function, OCP rationalisation, post-pregnancy timing counselling
  • Maintenance phase: azelaic acid or tretinoin monotherapy, tranexamic acid pulse, quarterly Q-switched toning to prevent relapse

Ready to Book Your Melasma Treatment in Thiruvalla?

DermaVue Thiruvalla — Iykara Peniel Tower, Opposite Indian Overseas Bank, Thukalassery. Mon–Sat 9 AM–7 PM, Sun 10 AM–6 PM.

WhatsApp Us 📞 +91 80860 00608

Comprehensive Pigmentation Treatment Guide

Frequently Asked Questions

Melasma is a chronic-relapsing condition; complete permanent cure is uncommon due to its multifactorial driver set (genetic susceptibility, sex hormones, ultraviolet and visible light). With structured combination therapy (Kligman trio + oral tranexamic acid + low-fluence Q-switched toning + rigorous daily iron-oxide sunscreen), most patients achieve 60–90% mMASI reduction and durable control. Lifelong maintenance and photoprotection are required to prevent relapse (Passeron, JEADV 2013).
Oral tranexamic acid 250 mg twice daily for 8–12 weeks is supported by multiple randomised trials (Bala et al., JAAD 2018; Del Rosario et al., JAAD 2018) showing significant mMASI reduction in refractory melasma. It is contraindicated in patients with personal or family history of deep vein thrombosis, pulmonary embolism, stroke, active malignancy, pregnancy, breastfeeding, or concurrent combined oral contraceptive use. DermaVue screens every candidate with detailed history, and where indicated, coagulation profile before prescribing.
Wood's lamp is a hand-held ultraviolet-A (365 nm) light used to classify melasma depth: epidermal melasma shows enhanced border contrast under the light and responds best to topicals and superficial peels; dermal melasma shows no contrast enhancement and requires oral tranexamic acid and low-fluence laser; mixed melasma combines both features. This classification drives treatment selection at DermaVue Thiruvalla and distinguishes our protocols from one-size-fits-all clinics.
Conventional mineral and chemical sunscreens block UVA and UVB but allow visible light — particularly high-energy blue light — to pass through. In Fitzpatrick IV–V skin, visible light independently triggers melanogenesis and drives melasma relapse (Mahmoud et al., JID 2010; Duteil et al., Pigment Cell Melanoma Res 2014). Iron-oxide pigments in tinted sunscreens reflect visible light and reduce melasma recurrence significantly compared to non-tinted SPF 50 alone (Dumbuya et al., JDD 2020). DermaVue prescribes iron-oxide tinted SPF 50+ PA++++ as standard.
Standard protocol is 6–10 sessions of low-fluence (1.6–3.4 J/cm², 1064 nm, 6 mm spot, large-spot handpiece) performed 2–4 weeks apart, combined with concurrent topical therapy. Maintenance sessions are recommended every 8–12 weeks. High-fluence Q-switched settings are avoided due to risk of paradoxical hyperpigmentation in Fitzpatrick IV–V skin (Chan et al., Dermatologic Surgery 2010). DermaVue uses a calibrated low-fluence protocol optimised for South Indian skin.
During pregnancy and lactation, the following are safe: azelaic acid 15–20%, glycolic acid peels ≤30%, and mineral sunscreens with iron oxides. The following are contraindicated: hydroquinone (absorbed systemically), topical and oral retinoids, oral tranexamic acid, and Q-switched laser (elective — deferred). DermaVue Thiruvalla designs pregnancy-safe bridging protocols with full treatment initiated post-delivery once breastfeeding is complete or earlier under obstetric guidance.
Yes, topical hydroquinone 2–4% remains the gold-standard topical depigmenting agent for 8–12 week courses under dermatologist supervision. Long-term unsupervised use above 4% or continuous use beyond 6 months risks exogenous ochronosis — a paradoxical blue-black hyperpigmentation documented in Indian skin (Charlín et al., Int J Dermatol). DermaVue prescribes hydroquinone as part of the modified Kligman trio for defined courses followed by azelaic acid or tretinoin maintenance, eliminating ochronosis risk.
Melasma is a chronic, symmetrical, hormonally and UV-driven hypermelanosis in predictable facial zones. Post-inflammatory hyperpigmentation (PIH) is a reactive hyperpigmentation following skin inflammation or injury (acne, eczema, procedural burn) and follows the distribution of the prior lesion. Treatment overlaps (topical lightening, peels, tranexamic acid) but PIH resolves faster and is not inherently chronic-relapsing. Dermoscopy and Wood's lamp differentiate reliably at DermaVue.
Over-the-counter combination creams containing super-potent steroids (clobetasol, betamethasone) produce rapid but deceptive lightening by atrophying the epidermis. Long-term use causes steroid-induced rosacea, telangiectasia, rebound hyperpigmentation, and permanent skin thinning — a common presentation among patients referred to DermaVue Thiruvalla after pharmacy cream misuse. IADVL has repeatedly campaigned against these products (IJDVL 2018). Only dermatologist-prescribed formulations should be used.
Thyroid dysfunction is a recognised contributor to refractory melasma, with autoimmune thyroiditis documented in a significant minority of female melasma patients (Lutfi et al., Arch Dermatol 1985). DermaVue Thiruvalla screens refractory melasma patients with TSH, free T4, and anti-TPO antibodies, and coordinates endocrine referral where indicated.
High-energy visible light (HEV, 400–500 nm blue light) from sunlight and digital screens independently induces melanogenesis in Fitzpatrick IV–VI skin (Duteil et al., 2014). While device exposure is far lower than sunlight, patients with severe or refractory melasma benefit from iron-oxide tinted sunscreen and device blue-light filters as adjunctive measures.
Yes — approximately 10% of Indian melasma patients are male, typically presenting with malar or mandibular patterns linked to outdoor occupational UV exposure rather than hormonal drivers (Sarkar et al., IJDVL 2014). Treatment mirrors the female protocol minus hormonal review, with particular emphasis on occupational photoprotection counselling.
Consultation and written personalised protocol: ₹300. Topical modified Kligman trio and adjuncts: prescription only, pharmacy cost. Oral tranexamic acid course: approximately ₹1,200 for 8–12 weeks. Low-fluence Q-switched Nd:YAG toning: ₹2,500–4,000 per session (packages available). Iron-oxide tinted medical sunscreen: ₹800–1,500 per month. Transparent package pricing is provided at consultation — no hidden costs.
Realistic expectations per Pigmentary Disorders Academy guidance: noticeable lightening by week 4–6, significant mMASI reduction by week 8–12, and maximal response typically around week 16–24. Patients who expect complete clearance within 2–3 weeks are counselled against high-concentration uncontrolled topicals which cause rebound pigmentation.
Yes — if performed incorrectly. Deep peels (phenol, 30%+ TCA) and aggressive laser resurfacing can cause paradoxical post-inflammatory hyperpigmentation in Fitzpatrick IV–V skin. DermaVue Thiruvalla uses only superficial peels validated for Indian skin (modified Jessner, mandelic 20–40%, glycolic 20–35%, salicylic 20–30%, TCA 15% spot) with pre-peel priming and rigorous post-peel sun avoidance.
Approximately 12 km from Pathanamthitta town and 15 km from Chengannur via the Pathanamthitta–Thiruvalla and MC Road routes. Patients from Mallappally, Kozhencherry, Adoor, Ranni and Mavelikkara regularly attend the Thukalassery clinic at Iykara Peniel Tower.

Explore More Services at DermaVue Thiruvalla

Acne Treatment in Thiruvalla Chemical Peels in Thiruvalla Dermatologist in Thiruvalla All Thiruvalla Services →

Book Your Consultation at DermaVue Thiruvalla

Board-certified dermatologists. Hospital-standard OT. US-FDA approved equipment. Physician-led care — not technician-run.

WhatsApp +91 80860 00608
📍 Iykara Peniel Tower, Opposite Indian Overseas Bank, Thukalassery, Thiruvalla 689101 🕘 Mon–Sat 9 AM–7 PM | Sun 10 AM–6 PM Get Directions →
Patient Stories

What Our Patients Say

Real experiences from patients across our 7 clinics.

4.8
★★★★★

Google Reviews · 7,200+ verified reviews

★★★★★

Visited this clinic for my skin concerns, and I'm extremely satisfied with the treatment. The doctor is knowledgeable and patient.

N
Naif
Thiruvananthapuram
★★★★★

The skin treatment at DermaVue was excellent. The consultation was detailed, and the treatment plan was explained thoroughly.

A
Aswathy S.
Kochi
★★★★★

Best dermatology clinic I've been to. The facilities are world-class and the results from my laser treatment exceeded expectations.

R
Ravi K.
Thiruvalla
Our Clinics

Visit Us at Any of Our 7 Clinics

Internationally certified dermatology care across Kerala and Tamil Nadu.

📍

Thiruvananthapuram

TC 42, 3003-2, Poojappura Main Rd, Kesari Nagar, Poojapura, Chengalloor, Thiruvananthapuram, Kerala 695012
Mon-Sat 9 AM – 7 PM · Sun 10 AM – 6 PM
📞 Call WhatsApp Map
📍

Kollam

1st Floor, Vellayittambalam, UMK Arcade, P.O, above HDFC bank, Kavanad, Kollam, Kerala 691003
Mon-Sat 9 AM – 7 PM · Sun 10 AM – 6 PM
📞 Call WhatsApp Map
📍

Thiruvalla

Iykara Peniel Tower, Opposite Indian Overseas Bank, Thukalassery, Thiruvalla, Kerala 689101
Mon-Sat 9 AM – 7 PM · Sun 10 AM – 6 PM
📞 Call WhatsApp Map
📍

Kottayam

101, Same as KFC Building, Second Floor, Zion Towers, Junction, SH 1, Thellakom, Kottayam, Kerala 686562
Mon-Sat 9 AM – 7 PM · Sun 10 AM – 6 PM
📞 Call WhatsApp Map
📍

Kochi · Aluva

Metro Rail Pillar No :57, Tamarind Rajadhani Building Near Pulinchodu NH-47, Aluva, Kerala 683101
Mon-Sat 9 AM – 7 PM · Sun 10 AM – 6 PM
📞 Call WhatsApp Map
📍

Thrissur

Ardra Arcade, opposite Akshaya Hotel, Jai Nagar, Jyothi Nagar, Punkunnam, Thrissur, Kerala 680002
Mon-Sat 9 AM – 7 PM · Sun 10 AM – 6 PM
📞 Call WhatsApp Map
📍

Coimbatore

460, Ponnaiyan St, Cross Cut Rd, Ram Nagar, Gandhipuram, Coimbatore, Tamil Nadu 641009
Mon-Sat 9 AM – 9 PM
📞 Call WhatsApp Map
Book Your Visit

Schedule a Consultation

Board-certified dermatologists across 7 clinics in Kerala & Tamil Nadu.

🔒 Your information is private and secure

Or reach us directly: +91 8086000608 · WhatsApp